entertainment -WSS

entertainment

author：explore 2025-09-03 11:47:15 - browse：121

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Health insurers say they are turning to AI to cut costs, improve care

Wikipedia

focus

WSS

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Search called off for baby washed away in Pennsylvania flash flood

Democrats decry new health bill for going easy on private equity

The battle over 'scope creep' and who gets to be called 'doctor'

The haunting brain science of long Covid

New Alzheimer's drugs heat up race for early detection blood tests

focus

entertainment

Wikipedia

Sports medicine is finally prioritizing gender equality

UHS says company favors patients whose insurance pays more

In Memoriam: Notable people who died in 2023

Akili, maker of video game for ADHD, to be acquired for 34 million

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

The cancer drug shortage isn’t new — and neither are the solutions

Addiction doctors spar with methadone clinics over legislation

Medicare proposal to cover medical devices draws a mixed reaction

How doctors’ personal politics affect patients

hotspot

STAT Report: Patient voices and perspectives

Rise in cancer among younger people worries and puzzles doctors

Average age of first period drops to 11.9 years, study shows

What will save rural psychiatry services? Higher Medicaid payments

Biohaven protein

Akili, maker of video game for ADHD, to be acquired for 34 million

Wikipedia

focus

hotspot

hotspot